Search Results | Diabetes | American Diabetes Association

1-20 of 166

Sort by

Sort Order Select

Journal Articles

High-Fat Diet–Induced DeSUMOylation of E4BP4 Promotes Lipid Droplet Biogenesis and Liver Steatosis in Mice

Sujuan Wang, Meichan Yang, Pei Li, Julian Sit, Audrey Wong, Kyle Rodrigues, Daniel Lank, Deqiang Zhang, Kezhong Zhang, Lei Yin, Xin Tong

Diabetes 2023;72(3):348–361

DOI: https://doi.org/10.2337/db22-0332

Published: 12 December 2022

View article titled, High-Fat Diet–Induced DeSUMOylation of E4BP4 Promotes Lipid Droplet Biogenesis and Liver Steatosis in Mice

Journal Articles

N-end Rule–Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage

Jiesi Xu, Zhenglong Liu, Jianxin Zhang, Siyu Chen, Wei Wang, Xuefan Zhao, Mei Zhen, Xun Huang

Diabetes 2023;72(2):210–222

DOI: https://doi.org/10.2337/db22-0362

Published: 08 November 2022

View article titled, N-end Rule–Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage

Journal Articles

Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity

Bastian Ramms, Dennis P. Pollow, Han Zhu, Chelsea Nora, Austin R. Harrington, Ibrahim Omar, Philip L.S.M. Gordts, Matthew Wortham, Maike Sander

Diabetes 2022;71(12):2513–2529

DOI: https://doi.org/10.2337/db21-1131

Published: 28 September 2022

View article titled, Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity

Journal Articles

PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

Edwige Schreyer, Cathy Obringer, Nadia Messaddeq, Bruno Kieffer, Paul Zimmet, Alexander Fleming, Tarekegn Geberhiwot, Vincent Marion

Diabetes 2022;71(9):2034–2047

DOI: https://doi.org/10.2337/db22-0058

Published: 13 July 2022

View article titled, PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

Meeting Abstracts

100-OR: Association of Recent Myocardial Infarction with Insulin Resistance and Fatty Liver Disease in Type 2 Diabetes

CLARA MÖSER, OANA P. ZAHARIA, FILIPPO C. MICHLOTTI, YULIYA KUPRIYANOVA, VERA SCHRAUWEN-HINDERLING, PAVEL BOBROV, VOLKER BURKART, MALTE KELM, JULIA M. SZENDROEDI, MICHAEL RODEN

Diabetes 2022;71(Supplement_1):100-OR

DOI: https://doi.org/10.2337/db22-100-OR

Published: 01 June 2022

View article titled, 100-OR: Association of Recent Myocardial Infarction with Insulin Resistance and Fatty Liver Disease in Type 2 Diabetes

Meeting Abstracts

1348-P: Roux-en-Y Gastric Bypass Prevents Obesity-Induced Fatty Liver by Modulating Liver Lipocalin Type Prostaglandin D2 Synthase Expression

ANKITA SRIVASTAVA, MATTHEW STEVENSON, THOMAS PALAIA, CHRIS HALL, JENNY LEE, LOUIS RAGOLIA

Diabetes 2022;71(Supplement_1):1348-P

DOI: https://doi.org/10.2337/db22-1348-P

Published: 01 June 2022

View article titled, 1348-P: Roux-en-Y Gastric Bypass Prevents Obesity-Induced Fatty Liver by Modulating Liver Lipocalin Type Prostaglandin D2 Synthase Expression

Meeting Abstracts

1207-P: Hepatic Steatosis Index and Fibrosis-4 Scores in Relation to Cardiometabolic Risk in Healthy Offspring of Parents with Type 2 Diabetes

BRIGIDA COLON BARRETO, KRISHMITA SIWAKOTI, CHIMAROKE EDEOGA, SOTONTE EBENIBO, SAMUEL DAGOGO-JACK

Diabetes 2022;71(Supplement_1):1207-P

DOI: https://doi.org/10.2337/db22-1207-P

Published: 01 June 2022

View article titled, 1207-P: Hepatic Steatosis Index and Fibrosis-4 Scores in Relation to Cardiometabolic Risk in Healthy Offspring of Parents with Type 2 Diabetes

Meeting Abstracts

1206-P: Association of Hepatic Steatosis Index (HSI) and Fibrosis (Fib) -4 Score with Prediabetes Risk in the POP-ABC Study: Potential Mechanisms

BRIGIDA COLON BARRETO, SOTONTE EBENIBO, SAMUEL DAGOGO-JACK

Diabetes 2022;71(Supplement_1):1206-P

DOI: https://doi.org/10.2337/db22-1206-P

Published: 01 June 2022

View article titled, 1206-P: Association of Hepatic Steatosis Index (HSI) and Fibrosis (Fib) -4 Score with Prediabetes Risk in the POP-ABC Study: Potential Mechanisms

Meeting Abstracts

121-OR: Alternate-Day Fasting Combined with Endurance Exercise for the Treatment of Fatty Liver Disease

MARK EZPELETA, KELSEY GABEL, KRISTA VARADY, SHUHAO LIN, SOFIA CIENFUEGOS

Diabetes 2022;71(Supplement_1):121-OR

DOI: https://doi.org/10.2337/db22-121-OR

Published: 01 June 2022

View article titled, 121-OR: Alternate-Day Fasting Combined with Endurance Exercise for the Treatment of Fatty Liver Disease

Meeting Abstracts

1151-P: Improved Liver Steatosis Scores in T2DM after Randomization to Bariatric Surgery Related to Improvement in Insulin Sensitivity and Cardiometabolic Risk

ALIMITHA MONALI KODALI, MICHELLE D. LUNDHOLM, ROMAN VANGOITSENHOVEN, JOHN P. KIRWAN, ALI AMINIAN, PHILIP SCHAUER, SANGEETA KASHYAP

Diabetes 2022;71(Supplement_1):1151-P

DOI: https://doi.org/10.2337/db22-1151-P

Published: 01 June 2022

View article titled, 1151-P: Improved Liver Steatosis Scores in T2DM after Randomization to Bariatric Surgery Related to Improvement in Insulin Sensitivity and Cardiometabolic Risk

Meeting Abstracts

736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity

JUANA CARRETERO GOMEZ, FRANCISCO JAVIER CARRASCO-SÁNCHEZ, JOSE MARIA FERNANDEZ, PEDRO CASADO, PANISH SOCIETY OF INTERNAL MEDICINE DIABETES, NUTRITION AND OBESITY WORKING GROUP OF S, JOSE CARLOS AREVALO LORIDO, JOSE PABLO MIRAMONTES GONZÁLEZ, JOSÉ MIGUEL SEGÍ-RIPOLL, JAVIER ENA

Diabetes 2022;71(Supplement_1):736-P

DOI: https://doi.org/10.2337/db22-736-P

Published: 01 June 2022

View article titled, 736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity

Meeting Abstracts

210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of Obesity or Fatty Liver

FERNANDO BRIL, RYAN PEARCE, TIMOTHY S. COLLIER, SRILAXMI KALAVALAPALLI, MICHAEL J. MCPHAUL, KENNETH CUSI

Diabetes 2022;71(Supplement_1):210-OR

DOI: https://doi.org/10.2337/db22-210-OR

Published: 01 June 2022

View article titled, 210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of Obesity or Fatty Liver

Meeting Abstracts

532-P: Voluntary Exercise during Food Restriction Promotes a Sustained Increase in Hepatic Oxidative Metabolism

STANISLAW DEJA, BLANKA KUCEJOVA, ADRIANNA MAURER, MONIKA N. MIZERSKA, XIAORONG FU, JOHN P. THYFAULT, SHAWN C. BURGESS

Diabetes 2022;71(Supplement_1):532-P

DOI: https://doi.org/10.2337/db22-532-P

Published: 01 June 2022

View article titled, 532-P: Voluntary Exercise during Food Restriction Promotes a Sustained Increase in Hepatic Oxidative Metabolism

Meeting Abstracts

120-OR: Hepatic Steatosis Is Inversely Associated with Improvement of Pancreatic Beta-Cell Function after Vertical Sleeve Gastrectomy in Patients with Type 2 Diabetes

AKINOBU NAKAMURA, YUKI OE, MAIKO KUSUMI, AIKA MIYA, HIROSHI NOMOTO, HIRAKU KAMEDA, KYUYONG CHO, KOJI OGAWA, YUMA EBIHARA, TATSUYA ATSUMI, HIDEAKI MIYOSHI

Diabetes 2022;71(Supplement_1):120-OR

DOI: https://doi.org/10.2337/db22-120-OR

Published: 01 June 2022

View article titled, 120-OR: Hepatic Steatosis Is Inversely Associated with Improvement of Pancreatic Beta-Cell Function after Vertical Sleeve Gastrectomy in Patients with Type 2 Diabetes

Meeting Abstracts

1091-P: Impact of Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease on Cardiovascular Risk in People with and without Type 2 Diabetes

YASUHIRO MATSUBAYASHI, KAZUYA FUJIHARA, MAYUKO H. YAMADA, YUTA YAGUCHI, MASAHIKO YAMAMOTO, HAJIME ISHIGURO, MASARU KITAZAWA, MIDORI IWANAGA, TAKAHO YAMADA, SATORU KODAMA, HIROHITO SONE

Diabetes 2022;71(Supplement_1):1091-P

DOI: https://doi.org/10.2337/db22-1091-P

Published: 01 June 2022

View article titled, 1091-P: Impact of Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease on Cardiovascular Risk in People with and without Type 2 Diabetes

Meeting Abstracts

97-OR: Fatty Liver Index (FLI) Is an Independent Risk Factor for All-Cause Mortality and Cardiovascular Events in Type 1 Diabetes (T1D) : A 10-Year Observational Study

MONIA GAROFOLO, DANIELA LUCCHESI, ELISA GUALDANI, PIERPAOLO FALCETTA, MASSIMO GIAMBALVO, PAOLO FRANCESCONI, STEFANO DEL PRATO, GIUSEPPE PENNO

Diabetes 2022;71(Supplement_1):97-OR

DOI: https://doi.org/10.2337/db22-97-OR

Published: 01 June 2022

View article titled, 97-OR: Fatty Liver Index (FLI) Is an Independent Risk Factor for All-Cause Mortality and Cardiovascular Events in Type 1 Diabetes (T1D) : A 10-Year Observational Study

Meeting Abstracts

1421-P: Long-Term Type 2 Diabetes Remission after Bariatric Surgery in Patients with and without Liver Steatosis

ANNE LAUTENBACH, MARIE WERNECKE, SEBASTIAN M. MEYHÖFER, SVENJA MEYHÖFER, FABIAN D. STOLL, JENS ABEREL

Diabetes 2022;71(Supplement_1):1421-P

DOI: https://doi.org/10.2337/db22-1421-P

Published: 01 June 2022

View article titled, 1421-P: Long-Term Type 2 Diabetes Remission after Bariatric Surgery in Patients with and without Liver Steatosis

Meeting Abstracts

273-OR: Postprandial Dysfunction in Metabolic Associated Fatty Liver Disease (MAFLD)

JOSEPHINE GRANDT, ANNE-SOFIE H. JENSEN, MIKKEL P. WERGE, ELIAS B. RASHU, ANDERS JUNKER, LISE HOBOLTH, CHRISTIAN MORTENSEN, MOGENS VYBERG, REZA SERIZAWA, SØREN MØLLER, LISE GLUUD, NICOLAI J. WEWER ALBRECHTSEN

Diabetes 2022;71(Supplement_1):273-OR

DOI: https://doi.org/10.2337/db22-273-OR

Published: 01 June 2022

View article titled, 273-OR: Postprandial Dysfunction in Metabolic Associated Fatty Liver Disease (MAFLD)

Meeting Abstracts

119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

JOHN B. PRINS, HARESSH SAJIIR, SAHAR KESHVARI, KUAN YAU WONG, JACK LOCKETT, MICHAEL MCGUCKIN, SUMAIRA Z. HASNAIN

Diabetes 2022;71(Supplement_1):119-LB

DOI: https://doi.org/10.2337/db22-119-LB

Published: 01 June 2022

View article titled, 119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

Journal Articles

Hepatic p38 Activation Modulates Systemic Metabolism Through FGF21-Mediated Interorgan Communication

Wei Liu, Chao Sun, Ying Yan, Hongchao Cao, Zhoumin Niu, Siyi Shen, Shengnan Liu, Yuting Wu, Yan Li, Lijian Hui, Yuying Li, Lin Zhao, Cheng Hu, Qiurong Ding, Jingjing Jiang, Hao Ying

Diabetes 2022;71(1):60–72

DOI: https://doi.org/10.2337/db21-0240

Published: 21 October 2021

View article titled, Hepatic p38 Activation Modulates Systemic Metabolism Through FGF21-Mediated Interorgan Communication

NARROW

High-Fat Diet–Induced DeSUMOylation of E4BP4 Promotes Lipid Droplet Biogenesis and Liver Steatosis in Mice

N-end Rule–Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage

Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity

PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

100-OR: Association of Recent Myocardial Infarction with Insulin Resistance and Fatty Liver Disease in Type 2 Diabetes

1348-P: Roux-en-Y Gastric Bypass Prevents Obesity-Induced Fatty Liver by Modulating Liver Lipocalin Type Prostaglandin D2 Synthase Expression

1207-P: Hepatic Steatosis Index and Fibrosis-4 Scores in Relation to Cardiometabolic Risk in Healthy Offspring of Parents with Type 2 Diabetes

1206-P: Association of Hepatic Steatosis Index (HSI) and Fibrosis (Fib) -4 Score with Prediabetes Risk in the POP-ABC Study: Potential Mechanisms

121-OR: Alternate-Day Fasting Combined with Endurance Exercise for the Treatment of Fatty Liver Disease

1151-P: Improved Liver Steatosis Scores in T2DM after Randomization to Bariatric Surgery Related to Improvement in Insulin Sensitivity and Cardiometabolic Risk

736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity

210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of Obesity or Fatty Liver

532-P: Voluntary Exercise during Food Restriction Promotes a Sustained Increase in Hepatic Oxidative Metabolism

120-OR: Hepatic Steatosis Is Inversely Associated with Improvement of Pancreatic Beta-Cell Function after Vertical Sleeve Gastrectomy in Patients with Type 2 Diabetes

1091-P: Impact of Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease on Cardiovascular Risk in People with and without Type 2 Diabetes

97-OR: Fatty Liver Index (FLI) Is an Independent Risk Factor for All-Cause Mortality and Cardiovascular Events in Type 1 Diabetes (T1D) : A 10-Year Observational Study

1421-P: Long-Term Type 2 Diabetes Remission after Bariatric Surgery in Patients with and without Liver Steatosis

273-OR: Postprandial Dysfunction in Metabolic Associated Fatty Liver Disease (MAFLD)

119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

Hepatic p38 Activation Modulates Systemic Metabolism Through FGF21-Mediated Interorgan Communication

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only